Fabry's disease, a disorder affecting the gene for the lysosomal enzyme agalactosidase A (a-GAL A), can cause accumulation of globotriaosylceramide (GL-3) in the vascular endothelial cells. Symptoms include pain, angiokeratoma, corneal clouding, and damage to the heart and kidneys. Human recombinant a-GAL A for use as an enzyme replacement therapy was launched in Japan in April 2004. Eleven ambulatory patients with Fabry's disease were given replacement a-GAL A therapy. Three patients died due to factors associated with Fabry's disease. The enzyme replacement therapies in the remaining eight patients continued safely without any notable adverse events. The following were observed: a lowering of the plasma levels of GL-3 in seven cases, an improvement in the daily activities in six cases, and a reduction in corneal clouding in three cases. Although careful observation is necessary, these results suggest that replacement a-GAL A therapy may be a safe and effective treatment of Fabry's disease.
Introduction
Fabry's disease is a genetic metabolic disorder characterized by a defect in the αgalactosidase A (α-GAL A) lysosomal enzyme that causes some glucolipids (sphingolipids), especially the ceramide trihexosides such as globotriaosylceramide (GL-3), to be progressively accumulated in various tissues and body fluids. 1 These accumulations are seen in the blood vessel walls, vascular endothelial cells and in the nervous system. The genotype is an X chromosome-linked recessive inheritance, and the locus exists on the X-chromosome (Xq21.33-q22). 1 In male patients, or classical hemizygotes, acroparaesthesias, angiokeratoma, hypohidrosis, corneal clouding and vascular diseases of the cerebral, cardiac and renal systems are often seen. Heterozygote female patients may experience symptoms ranging from silent to severe. The estimated frequency of Fabry's disease amongst men in Europe and in the USA is said to be about 1/40 000. 1 In Japan, approximately 250 patients with Fabry's disease have been identified in a current population of 125 million, equating to a frequency of 1/500 000.
In 1998, phase I/II studies on enzyme replacement therapy for Fabry's disease were initiated in the USA, using the human recombinant enzyme α-GAL A. 2 In the next year, phase III studies were started in Europe and in the USA. 3 Preparations were K Tsuboi Enzyme replacement therapy in Fabry's disease registered and then launched in Europe and in the USA in 2001 and in 2003, respectively. 4 In Japan, this preparation was governmentally recognized as an orphan drug in 1999 and clinical studies were started in 2000. 5 The governmental registration was made in January 2004 and, in April of the same year, the drug was launched. 4 By September 2006, almost 250 patients in Japan had been treated by this enzyme replacement therapy (Genzyme Corporation, Cambridge, MA, USA, unpublished). This is a novel therapeutic treatment of an uncommon hereditary disease. This paper reports and discusses the clinical courses of 11 Japanese patients given enzyme replacement therapy for Fabry's disease using the human recombinant enzyme α-GAL A.
Case reports
The case histories of six male hemizygote patients and five heterozygote female patients are briefly reported. All were ambulatory patients with Fabry's disease being treated at the Department of Hematology, Nagoya Central Hospital, Japan, with treatments starting between May 2003 and April 2006. Details of the patients' backgrounds and clinical characteristics are shown in Table 1 .
All the patients were being given enzyme replacement therapy in the form of human recombinant α-GAL A dissolved in 250 -500 ml 5% glucose solution and slowly infused at the dose of 1 mg/kg every 2 weeks. The infusion rate of the first administration was < 0.25 mg/min and the speed was gradually increased, as far as the patient could tolerate, to a maximum of 0.5 mg/min. Each infusion lasted 3 -4 h.
The Functional Independence Measure (FIM) 6,7 of the patients' activities of daily living was one of the measures used to assess the clinical efficacy of the enzyme replacement therapy. Others included improvements in hepatopathy, blood coagulation time and lowering of plasma GL-3 levels.
CASE 1 (36-YEAR OLD MAN)
When this patient's mother (case 8) received a genetic examination at another university hospital in 2003, both he and his mother were given the diagnosis of Fabry's disease. He visited Nagoya Central Hospital in 2004 and enzyme replacement therapy with α-GAL A was started in May of the same year. Urticaria, mild dyspnoea and palpitations, thought to be possible drug-induced transient reactions, were seen after the fourth administration. All these symptoms were treatable with hydroxyzine pamoate or hydrocortisone, and the reactions did not occur after the eighth administration. Plasma GL-3 levels were lowered from baseline, suggesting the treatment was efficacious.
CASE 2 (40-YEAR OLD MAN)
In 2003, this patient underwent detailed examinations, including an assessment of enzyme activities and skin and liver biopsies because of hypohidrosis, pain in the extremities, hepatopathy and a coagulation abnormality. Fabry's disease was diagnosed based on the findings of electron microscopy. He was receiving home nursing care, including oxygen therapy, due to chronic respiratory failure and visited Nagoya Central Hospital for treatment. Enzyme replacement therapy with α-GAL A was started in May 2004. Although his plasma GL-3 levels were starting to decrease, and he also showed improved FIM, hepatopathy (decrease in total bilirubin) and blood coagulation time (prothrombin time: 58% to 70%), suggesting that the treatment was efficacious, he died in July 2005 of acute pneumonia, and respiratory and cardiac failure. 
K Tsuboi Enzyme replacement therapy in Fabry's disease

K Tsuboi Enzyme replacement therapy in Fabry's disease CASE 3 (60-YEAR OLD MAN)
Fabry's disease was diagnosed in this patient in 1997 based on his enzyme activity and the results of a myocardial biopsy. As renal function gradually deteriorated, the patient required haemodialysis. In addition to longterm renal failure, he also showed chronic cardiac failure, cardiomyopathy and atrial fibrillation, as well as high-grade bradycardia. As a result, he underwent implantation of a cardiac pacemaker. He visited Nagoya Central Hospital in 2005 for treatment of worsening Fabry's disease, and enzyme replacement therapy with α-GAL A was initiated in August of the same year as a result of which he showed improved FIM.
CASE 4 (59-YEAR OLD MAN)
This patient received the diagnosis of Fabry's disease in 1982 based on the findings from biopsies for renal failure. Repeat biopsies performed in 1997 for cardiac failure and cardiac hypertrophy had similar findings. In 2002, haemodialysis was initiated because of worsening renal function. He visited Nagoya Central Hospital in August 2004, and in October of the same year enzyme replacement therapy with α-GAL A was begun. Although the patient made steady progress and his ability to perform the activities of daily living (FIM) was continuously improving, he died of a cardiac infarction and acute cardiac failure in January 2006.
CASE 5 (28-YEAR OLD MAN)
This patient was given a diagnosis of Fabry's disease in 1990 based on the findings of biopsy procedures and enzyme activity. Enzyme replacement therapy with α-GAL A was initiated in February 2005 by his former doctor because of deteriorating proteinuria and renal function. The patient was referred to Nagoya Central Hospital in 2006 for continuing treatment.
CASE 6 (35-YEAR OLD WOMAN)
This patient was given a diagnosis of hemizygous Fabry's disease in 2004 that was based on family history, enzyme activity, electron microscopic findings, as well as a genetic examination. Enzyme replacement therapy with α-GAL A was started in April 2006. The patient then showed improvement in FIM and plasma GL-3 was also lowered, suggesting the treatment was efficacious.
CASE 7 (58-YEAR OLD WOMAN)
About 20 years ago, this patient's brother had a cardiac disorder and was given a diagnosis of Fabry's disease. At that time our patient was also given a diagnosis of Fabry's disease (heterozygous type). She visited Nagoya Central Hospital in December 2004, complaining of ill health and pain in her extremities.
Her cardiac function deteriorated and enzyme replacement therapy with α-GAL A was initiated in 2007.
CASE 8 (64-YEAR OLD WOMAN)
During a detailed examination for myocardial hypertrophy, this patient was given a diagnosis of heterozygous Fabry's disease in 1975. She participated in a clinical study on α-GAL A and has been receiving the enzyme since May 2003. She was given an implantable pacemaker to treat high-grade bradycardia. This patient was referred to Nagoya Central Hospital in 2004 for continuing therapy and shows improvement in FIM.
CASE 9 (51-YEAR OLD WOMAN)
This patient's eldest brother was given a diagnosis of Fabry's disease in 1990; at that time the patient was also diagnosed with Fabry's disease (heterozygous type). Until she visited Nagoya Central Hospital in 2004, she had not been previously treated. Her examination findings showed myocardial K Tsuboi Enzyme replacement therapy in Fabry's disease hypertrophy, verticillate clouding of the cornea and pain in the extremities. Enzyme replacement therapy with α-GAL A was initiated in March 2005.
CASE 10 (53-YEAR OLD WOMAN)
This patient had agnogenic cardiac hypertrophy that was diagnosed at a neighbouring clinic around 1990. She then visited Nagoya Central Hospital for a more detailed examination. The diagnosis of heterozygous Fabry's disease was based on findings from myocardial biopsies and pathologic and electron microscopic studies in 2005. Enzyme replacement therapy with α-GAL A was started in July of that year.
CASE 11 (67-YEAR OLD WOMAN)
This patient was given a diagnosis of heterozygous Fabry's disease in 1975 based on enzyme activities and findings from an ophthalmic examination, skin biopsies and a genetic evaluation. The patient was under observation after implantation of a cardiac pacemaker for treatment of myocardial disorders and atrial fibrillation. She began therapy with α-GAL A at Nagoya Central Hospital in October 2004. There were improvements in an ophthalmic lesion and the patient's ability to perform everyday tasks (FIM); however, due to associated cardiac and renal failure, she was readmitted to hospital in 2005. In December 2005, during further exacerbation of Fabry's disease involving the heart and kidney, respiratory failure occurred and she died.
Discussion
Enzyme replacement therapy using α-GAL A was given to 11 patients with Fabry's disease (five men with classical hemizygote type and six women with heterozygote type) and the experiences reported in this paper support its efficacy and safety. Adverse events related to this enzyme, such as rigors, fever, headache, chills, pain related to Fabry's disease, hypertension, etc., have been reported 3 . Although urticaria, mild dyspnoea and palpitations were seen in case 1 after the fourth administration, they were all treatable with hydroxyzine pamoate or hydrocortisone and did not occur again after the eighth infusion. No complications as a result of the enzyme replacement therapy were seen in the four patients (cases 3, 4, 8 and 11) who underwent pacemaker implantation because of severe myocardial disorders; two of these patients (cases 3 and 4) were also undergoing haemodialysis due to severe kidney disorder.
Six patients (cases 2, 3, 4, 6, 8 and 11) had improvements in their FIM score. Improvements in hepatopathy (decrease in the total bilirubin) and blood coagulation time were seen in case 2. In three (cases 5, 6 and 11) out of four patients who had corneal clouding before starting enzyme replacement therapy, it improved after treatment. Plasma GL-3 levels were also lowered from baseline in seven patients (cases 1, 2, 5, 6, 7, 8 and 11). Phase I/II studies performed outside Japan that compared three different doses (0.3, 1.0 and 3.0 mg/kg) of α-GAL A in 15 men with Fabry's disease, showed that plasma levels of GL-3 were lowered in a dose-dependent manner. 2 In a multicentre, double-blind, placebo-controlled phase III study, 58 patients with Fabry's disease (29 patients each in the α-GAL A group and the placebo group) were given instillations of α-GAL A during 11 treatment periods within 20 weeks and the depositions of GL-3 in the endothelial cells of the renal capillaries were clearly decreased and the safety of α-GAL A was recognized. 3, 8, 9 After further continuous administration (6 -12 months), depositions of GL-3 in the kidney, heart and skin were K Tsuboi Enzyme replacement therapy in Fabry's disease reinvestigated and further decreases were seen. 3, 9 Although the lengths of treatment differed, these studies indicate the necessity of long-term administration. 8, 9 In the phase II study carried out in Japan, α-GAL A infusion was given 11 times (in 20 weeks) to 13 male patients with Fabry's disease (age ≥ 16 years), and the effect on the deposited GL-3 in the endothelial cells of the kidney, heart and skin was investigated. 5 As in studies conducted outside Japan, this study confirmed that the GL-3 deposits in each organ were clearly decreased, providing further evidence of the efficacy and the safety of this therapy.
There are many genetic abnormalities in Fabry's disease. More than 370 kinds of diversified variants that centre around the locus of chromosome X (Xq21.33-q22) have been reported. 10 These include point mutations (missense and nonsense mutations), partial deletions, insertions and splicing. In classical hemizygote male patients, acroparaesthesias, angiokeratoma, hypohidrosis, corneal clouding, vascular disorders of the cerebral, cardiac and renal areas are often seen. In contrast, heterozygote female patients may experience silent to severe symptoms. 11 Genetic analyses were performed on seven of the patients (cases 1, 5, 6, 8, 9, 10 and 11) . In cases 6 and 11, the partial deletion of approximately one base pair [Del1b(#188)] in exon 5 was found and, in cases 1 and 8, a missense mutation (E358K) was found in exon 7. Furthermore, in case 10, in codon 268, the leucine was mutated into the stop codon [10511del4]. The author believes that the pathological condition together with the efficacy and safety of treatment with α-GAL A should be independently assessed for each of these genetic variants.
In summary, the case studies reported here indicate that enzyme replacement therapy with α-GAL A might be effective and welltolerated for the treatment of patients with Fabry's disease. Further evaluation of the effects of long-term treatment are needed.
